What Canaloplasty Micro Catheters Do for Glaucoma Patients
Your vision seems fine. You are not squinting, and nothing hurts. Then a routine eye exam shows that the pressure inside your eye is higher than it should be.
This is a common way glaucoma comes to light, because the condition often causes no noticeable symptoms in its early stages. Primary open-angle glaucoma, the form named in the source report, is tied closely to age.
Canaloplasty micro catheters are specialized devices made for one job: reaching and treating Schlemm’s canal, part of the eye’s drainage pathway. IndexBox, a market research firm, describes them as single-use, sterile microcatheters for ab-interno canaloplasty. In its report on the global market, it says they allow a minimally invasive approach that reduces reliance on traditional filtration surgery.
The same report lists the procedure’s workflow stages: pre-operative planning and sizing, gonioscopic visualization and access, canal cannulation and viscodilation, and catheter withdrawal and wound closure.
The Numbers Behind the Forecast
IndexBox’s baseline scenario anticipates steady growth from 2026 to 2035, with a compound annual growth rate (CAGR) of 6.8%. That would bring its market index to roughly 193 by 2035, where 2025 equals 100.
That figure is an index, not a dollar amount. The report notes that indexed curves are used to compare scenarios when full absolute volumes are not publicly disclosed.
The report ties the growth to several factors:
Rising glaucoma prevalence as populations age, and the shift toward minimally invasive glaucoma surgery (MIGS) over traditional trabeculectomy. It also cites microcatheter design improvements such as better illumination and flexibility, and growing clinical evidence supporting canaloplasty. The expansion of ambulatory surgery centers (ASCs) and favorable reimbursement trends for MIGS in developed markets round out the list.
Who Is Buying These Devices
IndexBox estimates how demand splits across care settings:
Hospital and ASC procurement groups account for an estimated 45% of global demand, the largest share. Ophthalmology clinics and office-based surgery follow at an estimated 25%.
Academic and research institutions make up approximately 15%, mostly for clinical trials and device testing. Dedicated ambulatory surgery centers hold an estimated 10%, and government, military and NGO providers account for the remaining 5%.
The report names companies it treats as key participants, including New World Medical (maker of the OMNI Surgical System), Sight Sciences (VISCO 360 and OMNI systems) and Ellex Medical Lasers (iTrack microcatheter). Glaukos, Alcon and Bausch + Lomb also appear on its list.
Where Demand Is Growing Fastest
By IndexBox’s estimates, Asia-Pacific holds a 35% share and is the largest and fastest-growing region. The report points to a high prevalence of glaucoma, rising healthcare spending and more trained ophthalmologists, with China and India as key growth engines.
North America holds an estimated 30%, supported by advanced infrastructure and a growing number of ASCs and office-based surgeries. Europe follows at an estimated 20%, described as a mature market with strong clinical adoption.
Latin America holds an estimated 8% and the Middle East and Africa an estimated 7%. Both are described as emerging or nascent, held back by economic volatility, limited reimbursement or limited infrastructure.
What Could Slow Growth
The report is also direct about the constraints. A high regulatory burden and lengthy approval timelines affect new devices, and reimbursement coverage varies across regions.
It also lists the high cost of clinical trials and post-market surveillance, and limited awareness and training among ophthalmologists in some markets. Competition from alternative treatments, including laser therapy and traditional surgery, is another factor.
For patients, that last point matters. Canaloplasty is one option among several, and which approach suits a given eye is a decision for an ophthalmologist after examination.
When to See a Doctor
Because early glaucoma may cause no symptoms, routine eye exams are how it is usually found. An eye doctor typically checks eye pressure with tonometry and may examine the eye’s drainage angle with gonioscopy. Exams also commonly include a look at the optic nerve and a visual field test.
Age and a family history of glaucoma are well-recognized risk factors, so those are worth mentioning at your next appointment.
Seek urgent care if you have sudden, severe eye pain, especially with headache, nausea or vomiting, blurred vision, halos around lights, or a red eye. These symptoms can signal a rapid rise in eye pressure that needs prompt evaluation.
Your Next Step
If you are due for an eye exam, book one and ask whether your eye pressure and drainage angle were measured. If you already have a glaucoma diagnosis, ask your ophthalmologist how minimally invasive options compare with laser therapy and traditional surgery for your situation.
The market forecast shows where the technology is heading, but your own exam results should guide any treatment decision.
